“Launched in early 2024, Marseille-based biotech company Adcytherix has raised a record €105 million from a consortium of French and international investors, including Bpifrance and the Andera Partners and Kurma Partners funds. The company aims to position itself at the forefront of the antibody-drug conjugate (ADC) market.”

Click here to read the full article detailing the deal supported by McDermott’s life sciences and tax team.